Systemic arterial pressure is a dynamic and reactive physiological parameter depending on a great many factors. The endothelial cells of the vascular system are responsible for many biochemical reactions maintaining vascular homeostasis and therefore arterial pressure. Arterial hypertension, atherosclerosis and endothelial dysfunction constitute risk factors increasing morbidity
Introduction
The discovery of the endothelium as the main regulator of vascular tone has produced an enormous amount of clinical research trying to explain the physiology of this organ and its pathophysiology related to arterial hypertension.
The endothelial cells of the vascular system are responsible for many biological activities that hold vascular homeostasis. However, its dysfunction, which causes changes of modulation of the contractile state of a vessels smooth muscle, is according to experimental evidence closely associated with the appearance of premature arteriosclerosis 1, 2 and, in time, of arterial hypertension. The occurrence of hypertension and atherosclerosis increases with age 3 and in most cases arterial hypertension aggravates atherosclerotic injuries present in blood vessels as well as accelerating pathological changes of structure and function in 'target' organs. Much evidence also demonstrate clearly that endothelial dysfunction brings about a thickening of the subendothelial sheet, increased amounts of proteins, lipids and proinflammatory cells together with changes of viscoelastic properties of the arterial wall inducing alterations of the reactions to vasoactive stimuli. In this review we analyse the underlying pathophysiological mechanisms that relate endothelial dysfunction with arterial hypertension.
What is the endothelium?
Usually three sheets are distinguished on the wall of any blood vessel: intima, media and adventitia. Blood vessels, except sinusoids, are covered with a unique, continuous sheet of very specialized, metabolically active, polyhedral cells, the endothelial cells, positioned parallel to the longitudinal axis of and mortality of cardiovascular origin. These three elements are closely related and frequently act simultaneously damaging different organs. In this paper we review the physiology of the endothelium and the probable consequences of endothelial dysfunction on the pathophysiology of arterial pressure. Journal of Human Hypertension (2000) 14, Suppl 1, S20-S25. the vessel. In small vessels these cells possess a definite basal membrane underneath which fine elastic fibrils extend (subendothelium) establishing contact with the smooth muscle cells of the media. Such fibrils normally look like a continuous, retractile stripe, the inner elastic membrane. It is particularly conspicuous in the muscle arteries of medium thickness disappearing into the capillaries. Collagen and elastin fibrils derive from mesenchymal cells of fibrocytic or smooth muscle type within an amorphous, basal substance, rich in acid mucopolysacharides. The amount of collagen and basal substance increases with age.
The media consists of smooth muscle cells and elastic fibrils and the adventitia, the external coat of the arteries, is made of collagen fibrils, fibroblasts, nervous fibrils and small blood vessels. 4 The endothelium is arranged in such a way that it forms a monolayer covering the internal surface of arteries, veins, lymphatic vessels, cavities and cardiac valves as well as the cavernous body (corpus cavernosum) of the penis and clitoris, anterior eye chamber, pleura, lungs, and pericardial cavity, etc. Embryologically the endothelium stems from mesoderm and weighs about 2 kg. The functional unit of the endothelium, the endothelial cell, is polyhedral in shape showing a central thickness around 3 to 4 m and 0.1 m at the edges. Usually the endothelium is accompanied by a satellite cell, the periocyte, a cell present in blood and lymphatic vessels supporting and retaining the vascular tone.
Functions of the vascular endothelium
The endothelium is the basic structure of the intima pursuing a control function on circulation through the production of various vasoactive substances. In addition, it manufactures substances with enzymatic and immunological activity. Likewise the endothelium is visualized as a highly selective permeable barrier exerting a fundamental role upon the control of biochemical processes in blood, helping by this means to maintain vascular homeostasis ( Table 1) .
The endothelium possesses very specific characteristics like the production of autacoids with antagonistic effects involved in tone control and vascular homeostasis. It also has regulatory influences on vascular rearrangement, fibrinolysis, adhesion of leucocytes and activated platelets to the endothelium and on inflammatory processes. 5 In response to a variety of chemical and physical stimuli the endothelium produces a great deal of vasoactive and growth modulating substances as well as other factors mediating such functions as nitric oxide (NO), a known vasodilator 6 ( Table 2 ). Due to its strategic location between circulating blood and the vessel wall the endothelium interacts with neurohumoral cells and mediators, regulating in this way vascular contractility and cell composition. Stress and pulsating narrowing of the blood vessel walls are the most important stimuli for release of NO together with the release of systemic and local vasoactive substances. 7 The main vasodilators released from endothelial cells include NO, bradykinin and prostacyclin. NO is the most powerful endogenous vasodilator and it seems to be responsible for the maintenance of basal vascular tone. 5, 6, 8 It is synthesized in the endothelium cells from L-arginine through the action of NO synthetase. 9 Additional properties of NO include inhibitory effects on migration of smooth muscle cells, adhesion of leucocytes to the endo- Table 1 Functions of the vascular endothelium (1) Highly selective permeable barrier Regulation of plasma fluid, ions and macromolecules from and to the vascular space.
(2)
Immunological, enzymatic and inflammatory function Production of interleukine-I, which induces generation of T cells. Antigen supplies to immunocompetent cells. Local production of angiotensin-converting enzyme (ACE). Promotion of production of adhesion molecules that participate in the inflammatory reaction.
(3)
Detection of biochemical changes in blood and maintenance of homeostasis Recognition of variations of pH and oxygen and CO 2 concentration participating in this way in cardiovascular homeostasis.
(4)
Autocrine function Release of vasoactive substances, which regulate vascular tone:
Nitric oxide, prostacyclin Endothelin, thromboxane Angiotensin-I and angiotensin-II
Control of growth and cell proliferation Induction of the production of vascular smooth muscle promotors. Induction of the production of vascular smooth muscle inhibitors. Induction of adhesion molecules for blood cells.
(6)
Haemostatic function Insurance of blood fluidity. Thromboresistant activity through anticoagulant, fibrinolytic and platelet antiaggregation properties. Promotion of the production of procoagulant and anticoagulant substances: PGI 2 , endothelin I, fibronectin, tissue-type plasminogen activator and heparan. thelium and platelets aggregation. The endothelium mediates the ability of the blood vessels to vary its architecture in response to haemodynamic changes. Numerous works demonstrate that NO produced by the endothelium is the main contributor to this remodelling participating critically as a negative regulator for the proliferation of vessels smooth muscle in response to stimuli. 10 Bradykinin is a potent vasodilator at the same time stimulating the release of NO and hyperpolarizing factor derived from endothelium, both of which are vasodilatory substances. 5 Bradykinin exerts its vasodilatory activity mainly through the release of NO. Other effects of bradykinin are to promote the production of tissue-type plasminogen activator (t-PA) supporting by this means the maintenance of the fibrocytic balance. It also exhibits an antiaggregant effect upon the platelets through the release of NO and prostacyclin.
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Apparently the inhibitors of the angiotensin-converting enzyme (ACE) act by accumulation of bradykinin. 11 The most important form of endotheliumderived vasoconstrictor substances comprise angiotensin II and endothelin. Angiotensin II is a powerful vasoconstrictor with various effects on blood vessel structure and on vascular homeostasis (Figure 1 ). 12 Angiotensin II increases the production of type 1 inhibitor of the plasminogen activator and the primary endogenous inhibitor of t-PA and promotes vascular growth and in addition stimulating the generation of different growth factors. Angiotensin II also elevates the response of platelets to aggregation against direct platelet agonists and stimulates the production of endothelin, which is considered the most potent endogenous vasoconstrictor.
Recently more attention is being given to the possible role of another biologically active component of the angiotensin system, angiotensin III, also called [des-Asp] or angiotensin. [2] [3] [4] [5] [6] [7] [8] It is made by the catalytic action of aminopeptidase upon angiotensin II or through the action of ACE on angiotensin I. Angiotensins III and II have qualitatively similar effects. Angiotensin III has almost the same action as angiotensin II in the promotion of aldosterone secretion. However, angiotensin III possess only 10 to 25% of the power of angiotensin II to increase arterial pressure. Angiotensin-(1-7) an aminoterminal heptapeptide, is produced in different tissues. In blood vessels its production is the consequence of the action of tissue endopeptidases upon angiotensin I and angiotensin II. 13 In vascular smooth muscles it can be obtained from angiotensins I and II through the action of metalloendopeptidases and propylendopeptidases. Evidence from a number of animal studies suggests that angiotensin-(1-7) is a vasodilator that may confer cardioprotective effects by opposing the action of angiotensin II on growth and reactivity of blood vessels. Unlike angiotensin II angiotensin-(1-7) causes no vasoconstriction, aldosterone release, thirst or induction of noradrenergic neurotransmission. Its vasodilatory effect is mediated by the production of endothelial NO and bradykinin.
14 Endothelin promotes the proliferation of smooth muscle cells and the secretion of extracellular matrix, which contribute to the formation of atherosclerotic plaque. Endothelins are regulatory peptides distributed among many organic systems that produce powerful physiological effects. It is the most potent known vasoconstrictor substance and from a pathological stand-point seems to be involved in several diseases related to the vascular system such as arterial hypertension (AHT), pulmonary hypertension, pre-eclampsia, ischaemic cardiopathy, renal insufficiency, subarachnoid haemorrhage and brain ischaemia. 15 The similarity of endothelin with neurotoxins suggests that its action consists in the modulation of the ion channels. Its effects depend on Ca presence and is not modified by cholinergic or serotoninergic block. Today it is known that ET-1 promotes Ca uptake to the cells by two mechanisms: (1) direct Ca mobilization independent of dihydropyridines; and (2) through the Ca channels.
The role that ET-1 plays in the regulation of vascular tone is beyond doubt. Nevertheless an intact endothelium is required to observe any effect since the actions of both prostacyclin and NO, stimulated by ET-1, must be added to antagonise endothelin vasoconstrictor activity. All these mechanisms together control vascular tone and blood flow in the systemic or local environment according to its needs.
It is well known that ET-1 is stimulated by noradrenaline, thrombine, hypoxia, increased transmural pressure and distension of the arteries. Insulin stimulates the synthesis and discharge of ET-1 which partially explains arterial hypertension by hyperinsulinaemia and the existing connection between insulin resistance and arterial pressure. One of the fundamental points about the pathological function of ET-1 is its mitogenic effect, particularly on the ateroma plaque. 12 The normal endothelium functions in an inhibitory way maintaining the relaxation of vascular tone and inhibiting Endothelial dysfunction in arterial hypertension F Contreras et al S23 smooth muscle growth, adhesion, and aggregation of platelets and thrombosis. It is evident that any alteration of this inhibitory function of the endothelium can be followed by a vasoconstrictive response with elevation of peripheral vascular resistance and arterial pressure, stimulation of the growth of vascular smooth muscle and increase of platelets adhesion and aggregation with ensuing thrombogenic effects.
Endothelial dysfunction
The term 'endothelial dysfunction' is recently being used to identify general abnormalities of the functions that usually perform the endothelium. Endothelial dysfunction is widely accepted as an early event in the pathogenesis of cardiovascular diseases. This observation is based on the significance of the endothelium in the preservation of cardiovascular health. Endothelial dysfunction and coronary arterial disease are closely related to arterial hypertension (AHT), hypercholesterolaemia, diabetes mellitus and tobacco smoking, 16, 17 which constitute risk factors predisposing the development of atherosclerosis since they enforce endothelial dysfunction and alteration of smooth muscle cells as well as coagulation disturbances 17 ( Figure 2 ). Endothelial injury produces denuded endothelium areas, breakage of the intima and necrosis of the smooth muscle cells. Exposure of the subendothelium and the components of the media to the blood stream activates the haemostatic system. 18 Vasodilator damage originated by endothelial dysfunction might be due to a decrease in NO production or slower response to NO by the vessel smooth muscles. 17 In the majority of vascular dis- Figure 2 Factors enhancing endothelial dysfunction. Endothelial cells might modify NO levels by releasing more oxygen-free radicals.
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eases the vasodilator function is attenuated. In advanced artheriosclerotic lesions the endotheliumdependent vasodilatation might be even abolished. 19 There exist several grades and forms of endothelial dysfunction: (1) damage of the Galphai proteins; (2) a decreased release of NO, prostacyclin and or hyperpolarizing factor derived from endothelial (EDHF); (3) increase of endoperoxidases discharge; (4) increase in reactive oxygen species; (5) increase in the production of endothelin 1 (ET-1); and (6) decrease of smooth muscle sensitivity to NO, prostacyclin and/or EDHF.
Bradykinin and angiotensin II levels within the vascular wall are controlled by ACE. ACE degrades bradykinin and produces angiotensin II. Bradykinin stimulates the endothelial cells to release vasodilatory substances. The activity of kinins holds up in spite of endothelial dysfunction except by severe arterial lesions. Angiotensin II might be partly responsible for endothelial dysfunction inasmuch as it induces resistance to the vasodilator action from NO. For this reason if the production of angiotensin II is arrested the direct and indirect vasoconstrictor effects of this peptide are blocked. 20 A decline in NO production could be ascribed to: (1) changes in intracellular availability of L-arginine; (2) a decrease in the NO synthetase activity; and (3) alteration of NO release mediated by receptors in response to pharmacological or laminar stress. Rising of NO degradation derives from the increase of free oxygen radicals generated in the endothelium and/or vascular smooth muscles. with blood vessel damage is nowadays widely accepted as well as the fact that AHT tends to worsen the endothelial vasodilatory function. [21] [22] [23] Hypertension occurs in association with morphological and functional changes of the endothelium expressed partly by subendothelial fibrin accumulation and infiltration of endothelial cells and through modification of processes mediated by NO, endothelin and cyclooxygenase products affecting the regulation of endothelium-dependent vascular tone.
Patients suffering from AHT show impairment of endothelium-dependent vasodilatation associated with an anomalous function of the endothelial NO system. According to different findings reactive oxygen species are also involved in the pathogenesis of hypertension and several connected disorders. As a consequence of alterations in the balance between vasoconstrictor substances such as thromboxane and isoprostanes and vasodilators like NO, reactive oxygen species contribute to endothelium-dependent contractions and to the increase of peripheral vascular resistance (Figure 2 ). Numerous oxygenfree radicals act modifying essential biological molecules like lipids, proteins and DNA producing changes in their function. Cytotoxic products and formation of fat-filled macrophages contribute to the development of atherosclerotic plaque. In addition, each peroxide radical can propagate itself many times, an event that, if it is not under control, might produce an extensive lipid peroxidation.
The formation of O 2 in the vascular wall is associated with abnormal situations like hypercholesterolaemia, although its metabolic pathway has not been clearly identified. Furthermore its potential toxic role was deduced only because of the presence of superoxide dismutase 24 that works as an oxygen sweeper mechanism and is concentrated especially in the intima layer. For that reason antioxydant agents must be considered in AHT therapy. 25 Sodium plays also an important part on the pathogenesis of AHT, a major factor for cardiovascular disease. Studies of endothelium involvement in vascular changes produced by salt-induced or salt sensitive AHT suggest that ET-1 acts as a local mediator of vascular dysfunction and aortic hypertrophy. Antagonists of ET-1 receptors possess a crucial therapeutic potential by diminishing ET-1 levels improving endothelial function and preventing structural changes caused by salt sensitive AHT. 25 A potential role of ET-1 as mediator in vascular hypertrophy in response to angiotensin II has been demonstrated 26 as well as the association of ET-1 with remodelling of the intima by arteriosclerosis as a reaction to vessel damage. 27 The inbalance between NO and angiotensin II activities observed by endothelial dysfunction and the presence of coronary disease risk factors causes oxydative stress, which derives from the excessive production of oxygen-free radicals and the subsequent catabolism of NO. Angiotensin II-induced AHT exhibits an increase in the production of oxygen-free radicals promoting oxydative stress. 28 The higher generation of oxygen-free radicals opposes the effects of NO, stimulates the activity of adhesion molecules and favours leucocytes sticking to the endothelium, which leads to acute inflammatory response, proliferation of smooth muscle cells and additional synthesis of extracellular matrix contributing in this way to the pathogenesis of cardiovascular diseases. 29 Endothelial dysfunction is also present in different conditions accepted as risk factors for arteriosclerosis such as AHT, diabetes mellitus, tobacco smoking and dislipidaemia (Figure 2) . In AHT, anomalies have been reported in fibrinolysis, endothelial function, and glucose and lipid metabolism. The results indicated that fibrinolytic alterations are linked with endothelial dysfunction and disorders of glucose and lipid metabolism. Treatment based on ACE inhibitors improves fibrinolysis and endothelial dysfunction. 30 With severe arterial hypertension high levels of hepatocyte growth factor (HGF) have been found. The amounts of HGF-a member of endotheliumspecific growth factors-were more elevated when AHT was accompanied by systemic complications. Nevertheless it diminishes significantly to normal values as soon as hypertensive therapy has been applied. HGF may then represent a new index for the severity of AHT. 31 It is interesting to note that the endotheliumdependent lower vasodilatation present in hypertensive persons can be demonstrated using agonists like acetylcholine and bradykinin, substances acting through different receptors and intracellular signals pathways. 32 This suggests that endothelial dysfunction by hypertension should not be ascribed to defects of the muscarine receptors.
Much evidence indicate that the endotheliumdependent lower vasodilatation, at least in some forms of hypertension, is not due solely to changes in NO mediated mechanisms. Endothelium-derived contraction factors produced in higher quantities can participate too. [33] [34] [35] However, in rats with spontaneous hypertension the low vasodilatory response to different agonists (serotonin, acetylcholine, calcium ionophores) can be partially or completely restored by inhibitors of the synthesis of prostaglandins or by blocking prostaglandins H 2 receptors. 35, 36 The metabolism of arachidonic acid may be probably altered, which increases the production of vasoconstrictor prostaglandins. Similarly, in individuals with essential hypertension the lower vasodilatation in response to acetylcholine in forearm circulation is partially recovered with previous indomethazine treatment, an inhibitor of prostaglandins synthesis.
Obviously endothelial dysfunction is always present in hypertension, although it is not known if we are dealing with a primary phenomenon or the consequence of a higher arterial pressure. It appears in established but not in early hypertension and can be reversed through antihypertensive drugs. Therefore, apparently in almost all animal hypertension models, endothelial dysfunction is a consequence of, and not a cause of the problem.
Given the fundamental role of endothelial dysfunction as a central mechanism involved in many Endothelial dysfunction in arterial hypertension F Contreras et al S25 risk factor conditions as well as in the generation of the proper disease, it seems reasonable to apply a therapy having direct effects on the endothelial function.
